BRAF/600E MUTATION STATUS AND INTRATUMORAL IMMUNE MICROENVIRONMENT IN PAPILLARY THYROID CARCINOMA WITH HASHIMOTO’S THYROIDITIS
Abstract
BRAF/V600E is the most frequently detected mutation in thyroid papillary carcinomas, with the incidence of 45-80%. The aim of our study was to detect the peculiarities of BRAF/V600E mutation and intratumoral immune microenvironment in thyroid papillary carcinomas in cases with or without Hashimoto’s thyroiditis. Standard immunohistochemistry was used to detect BRAF/V600E mutation status, and the infiltration with CD3, CD8 T cells and CD68 macrophages. In addition, we have investigated the histopathological characteristics of papillary thyroid carcinoma. The results of our study indicated that thyroid papillary carcinomas with Hashimoto’s thyroiditis is characterised with lower malignancy grade. The presence of Hashimoto’s thyroiditis does not influence the lymphocytic infiltration. There is the trend of higher frequency of BRAF/V600E mutation in higher grade tumors. The lymphocyte and macrophage infiltration is more frequently seen in cases with BRAF/V600E mutation.
Downloads
References
M. A. Zaballos and P. Santisteban, “Key signaling pathways in thyroid cancer,” 2017.
R. Ren et al., “Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation,” Mod. Pathol., vol. 34, no. 2, pp. 438–444, 2021.
M. Drosten and M. Barbacid, “Targeting the MAPK Pathway in KRAS-Driven Tumors.,” Cancer Cell, vol. 37, no. 4, pp. 543–550, Apr. 2020.
R. D. Hall and R. R. Kudchadkar, “BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.,” Cancer Control, vol. 21, no. 3, pp. 221–230, Jul. 2014.
J. Ge et al., “The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer.,” J. Cancer, vol. 11, no. 4, pp. 932–939, 2020.
M. Paja Fano, A. Ugalde Olano, E. Fuertes Thomas, and A. Oleaga Alday, “Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.,” Endocrinol. diabetes y Nutr., vol. 64, no. 2, pp. 75–81, Feb. 2017.
N. Mitsutake et al., “BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl.,” Sci. Rep., vol. 5, p. 16976, Nov. 2015.
X. Gan et al., “Prognostic implications of the BRAF ‑ V600 E mutation in papillary thyroid carcinoma based on a new cut ‑ off age stratification,” pp. 631–640, 2020.
L. Wang, W. Li, H. Ye, and L. Niu, “Impact of Hashimotoas thyroiditis on clinicopathologic features of papillary thyroid carcinoma associated with infiltration of tumor-infiltrating lymphocytes.,” Int. J. Clin. Exp. Pathol., vol. 11, no. 5, pp. 2768–2775, 2018.
C. Calangiu, C. Simionescu, A. Stepan, M. Parnov, and L. Cercelaru, “The assessment of prognostic histopatholgical parameters depending on histological patterns of papillary thyroid carcinoma.,” Curr. Heal. Sci. J., vol. 40, no. 1, pp. 37–41, Jan. 2014.
V. Marotta et al., “BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto’s thyroiditis lymphocytic infiltration is present.,” Clin. Endocrinol. (Oxf)., vol. 79, no. 5, pp. 733–738, Nov. 2013.
